Transcription
Pharmaceutical Management AgencyUpdateNew ZealandPharmaceutical ScheduleEffective 1 August 2011Cumulative for May, June, July and August 2011Section H for August 2011
ContentsSummary of PHARMAC decisions effective 1 August 2011. 3Mental health medication brand change workshops for pharmacists. 4Fluconazole powder for oral suspension – new listing. 4Venlafaxine – new brand listed. 5Omeprazole – new listing. 5Rituximab – wider access and subsidy and price decrease. 5Sodium chloride 7% nebulising solution – change to packaging. 6Glyceryl trinitrate spray – delay in listing AFT’s Glytrin. 6Minor amendments to General Rules. 6Tender News. 7Looking Forward. 7Sole Subsidised Supply products cumulative to August 2011. 8New Listings. 15Changes to Restrictions. 22Changes to Subsidy and Manufacturer’s Price. 45Changes to General Rules. 52Changes to Brand Name. 54Changes to Section E Part I. 54Changes to Section F Part II. 55Changes to Sole Subsidised Supply. 55Delisted Items. 56Items to be Delisted. 59Section H changes to Part II. 62Section H changes to General Rules. 64Index. 662
Summary of Pharmac decisionseffective 1 August 2011New listings (page 15) Omeprazole (Omezol Relief) cap 10 mg, 20 mg and 40 mg Fluconazole (Diflucan) powder for oral suspension 10 mg per ml, 35 ml –Special Authority – Retail pharmacy Venlafaxine (Arrow-Venlafaxine XR) tab 37.5 mg, 75 mg and 150 mg – SpecialAuthority – Retail pharmacyChanges to restrictions (pages 22-26) Dexamphetamine sulphate (PSM) tab 5 mg – amended Special Authoritycriteria Methylphenidate hydrochloride tab immediate-release 5 mg (Rubifen), 10 mg(Ritalin and Rubifen) and 20 mg (Rubifen), and tab sustained-release 20 mg(Rubifen SR and Ritalin SR) – amended Special Authority criteria Methylphenidate hydrochloride extended-release tab extended-release 18 mg,27 mg, 36 mg and 54 mg (Concerta), and cap modified-release 10 mg, 20 mg,30 mg and 40 mg (Ritalin LA) – amended Special Authority criteria Daunorubicin (Pfizer) inj 2 mg per ml, 10 ml – removal of Section 29 Rituximab inj 100 mg per 10 ml vial and 500 mg per 50 ml vial (Mabthera) andinj 1 mg for ECP (Baxter) – amended Special Authority criteriaIncreased subsidy (page 45) Mometasone furoate (Elocon) lotn 0.1%, 30 ml OP Oxazepam (Ox-Pam) tab 10 mg and 15 mg Interferon beta-1-alpha (Avonex) inj 6 million iu prefilled syringe and vialDecreased subsidy (page 45) Iron polymaltose (Ferrum H) inj 50 mg per ml, 2 ml Amlodipine (Apo-Amlodipine) tab 5 mg and 10 mg Sildenafil (Viagra) tab 25 mg, 50 mg and 100 mg Ibuprofen (Brufen SR) tab long-acting 800 mg Morphine sulphate (LA-Morph) tab long-acting 30 mg and 100 mg Rituximab inj 100 mg per 10 ml vial and 500 mg per 50 ml vial (Mabthera) andinj 1 mg for ECP (Baxter)3
4Pharmaceutical Schedule - Update NewsMental health medicationbrand change workshopsfor pharmacistsA training programme is being heldto support pharmacists in providingappropriate support and counselling topeople changing brands of mental healthmedication.The programme includes a 4-hour practicalworkshop that will provide an overviewof some common mental health illnessesand medications, using olanzapine as anexample. Pharmacists will be eligible toreceive 10 College CE credits and the coursewill contribute to Continuing ProfessionalDevelopment (CPD) credits.To register phone 04 381 6382 or email Helen.teo@blueprint.co.nz. More information canbe found on the PHARMAC website at ole powder for oral suspension – new listingFluconazole powder for oral suspension 10this is a reconstituted solution, the wastagemg per ml (Diflucan) will be fully subsidisedrule that currently applies to antibiotics willfrom 1 August 2011 subject to Specialapply to fluconazole, requiring pharmacistsAuthority restrictions for prophylaxis for, orto enter the amount required on thetreatment of, systemic candidiasis whereprescription and claim the remainder of thethe patient is unable to swallow capsules. Aspack (if any) as wastage.
Pharmaceutical Schedule - Update NewsVenlafaxine – new brand listedA new brand of venlafaxine will beSchedule subject to its current Specialsubsidised from 1 August 2011. Arrow-Authority restrictionsVenlafaxine XR 37.5 mg, 75 mg and 150 mgtablets will be funded subject to the sameSpecial Authority criteria as the Efexor XRbrand of venlafaxine.The Efexor XR brand will continue to belisted in Section B of the PharmaceuticalThere is no planned sole supplyarrangement for venlafaxine at this time.We have been informed by the supplier thatstock of Arrow-Venlafaxine XR will not beavailable until early to mid August.Omeprazole – new listingA new brand of omeprazole, Omezol Relief,will be subsidised from 1 August 2011.Omezol Relief 10 mg, 20 mg and 40 mgis supplied by Mylan and will be the solesubsidised brand of omeprazole from 1January 2012. Dr Reddy’s Omeprazole willbe reference priced to Omezol Relief from 1October 2011.Rituximab – wider access and subsidy and pricedecreaseFrom 1 August the Special Authorityapplying to the Pharmaceutical CancerTreatment rituximab (MabThera) will bewidened to include funding for patientswith Chronic Lymphocytic Leukemia (CLL).Rituximab will be funded for treatment naïveCLL patients as well as in rituximab naïvepatients whose CLL disease has relapsedfollowing up to three prior lines of therapy.In addition, from 1 August the price andsubsidies for rituximab inj 100 mg per 10 mlvial (MabThera), inj 500 mg per 50 ml vial(MabThera) and inj 1 mg for ECP (Baxter) willbe reduced.5
6Pharmaceutical Schedule - Update NewsSodium chloride 7% nebulising solution – change topackagingIn future the 90 ml bottle of SodiumChloride 7% will not be sealed with a metalband. This means that patients will be ableto measure the required volume withouthaving to use a syringe to withdraw thesolution.Glyceryl trinitrate spray – delay in listing AFT’s GlytrinThe listing date of AFT’s glyceryl trinitratespray, 400 µg per dose, has been delayedfrom 1 September 2011 until 1 January 2012.We expect that AFT will have stock availableby mid-January 2012. Douglas’ NitrolingualPumpspray will continue to be listed andfully subsidised until 1 March 2012 whenit will be reference priced to AFT’s Glytrin.Douglas’ Nitrolingual Pumpspray will bedelisted on 1 June 2012.Minor amendments to General RulesFollowing the decision to combine the Community and Pharmaceutical Cancer TreatmentBudgets from 1 July 2011, some minor consequential amendments to the General Ruleshave been made.
Tender NewsSole Subsidised Supply changes – effective 1 September 2011Chemical NamePresentation; Pack sizeSole Subsidised Supplybrand (and supplier)Ipratropium bromideAqueous nasal spray, 0.03%; 15 ml OPUnivent (Rex Medical)Naltrexone hydrochlorideTab 50 mg; 30 tabNaltraccord (Arrow)SumatriptanInj 12 mg per ml, 0.5 ml; 2 inj OPArrow-Sumatriptan (Arrow)Tamoxifen citrateTab 20 mg; 100 tabGenox (Mylan)Looking ForwardThis section is designed to alert both pharmacists and prescribers to possible futurechanges to the Pharmaceutical Schedule. It may also assist pharmacists, distributorsand wholesalers to manage stock levels.Possible decisions for implementation 1 September 2011 Adalimumab inj 40 mg per 0.8 ml prefilled pen and syringe (HumiraPen andHumira) – amended Special Authority criteria Etanercept (Enbrel) inj 25 mg, and inj 50 mg autoinjector and prefilled syringe– amended Special Authority criteria Fludarabine (Baxter) inj 50 mg for ECP – subsidy decrease Imiquimod (Aldara) crm 5%, sachet – subsidy decrease Olanzapine (Zyprexa) tab 2.5 mg, 5 mg and 10 mg – subsidy decrease andremove Special Authority Olanzapine (Zyprexa Zydis) wafer 5 mg and 10 mg – subsidy decrease andremove Special Authority7
Sole Subsidised Supply Products – cumulative to August 2011Generic NamePresentationBrand Name Expiry Date*Abacabir sulphateOral liq 20 mg per mlTab 300 mgZiagenZiagen2014AcarboseTab 50 mg & 100 mgGlucobay2012AciclovirTab dispersible 200 mg, 400 mg &800 mgLovir2013AmitriptylineTab 25 mg & 50 mgAmitrip2014AmoxycillinCap 250 mg & 500 mgGrans for oral liq 250 mg per 5 mlAlphamoxOspamox20132012Amoxycillin clavulanateGrans for oral liq amoxycillin 125 mgwith potassium clavulanate 31.25 mgper 5 mlGrans for oral liq amoxycillin 250 mgwith potassium clavulanate 62.5 mgper 5 mlCuram2012Ascorbic acidTab 100 mgVitala-C2013AspirinTab 100 mgTab dispersible 300 mgEthics Aspirin ECEthics Aspirin20138CuramAtenololTab 50 mg & 100 mgAtenolol Tablet USP2012Atropine sulphateInj 600 µg, 1 mlAstraZeneca2012AzathioprineTab 50 mgInj 50 mgImuprineImuran2013AzithromycinTab 500 mgArrow-Azithromycin2012BaclofenTab 10 mgPacifen2012Betamethasone valerateScalp app 0.1%Beta Scalp2012BisacodylTab 5 mgLax-Tab2013CalamineCrm, aqueous, BPLotn, BPhealthEAPI2012CalcitriolCap 0.25 µg & 0.5 µgAirflow2012CaptoprilTab 12.5 mg, 25 mg & 50 mgOral liq 5 mg per mlm-CaptorprilCapoten2013Cefaclor monohydrateGrans for oral liq 125 mg per 5 mlRanbaxy-Cefaclor2013Ceftriaxone sodiumInj 500 mgInj 1 gVeracolAspen Ceftriaxone2013Cephalexin monohydrateGrans for oral liq 125 mg per 5 mlGrans for oral liq 250 mg per 5 mlCefalexin SandozCefalexin Sandoz2012CetomacrogolCrm BPPSM2013ChloramphenicolEye drops 0.5%Eye oint 1%ChlorafastChlorsig2012Chlorhexidine gluconateHandrub 1% with ethanol 70%healthE2012CiclopiroxolamineNail soln 8%Batrafen2012CilazaprilTab 0.5 mg, 2.5 mg & 5 mgZapril2013*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated unless otherwise stated. Please note thatSole Subsidised Supply may have been awarded for a wider scope than just those presentation(s) listed in the above table.
Sole Subsidised Supply Products – cumulative to August 2011Generic NamePresentationBrand Name Expiry Date*Cilazapril withhydrochlorothiazideTab 5 mg with hydrochlorothiazide12.5 mgInhibace Plus2013Clobetasol propionateCrm 0.05%Oint 0.05%Scalp app 0.05%DermolDermolDermol2012ClonidineTDDS 2.5 mg, 100 µg per dayTDDS 5 mg, 200 µg per dayTDDS 7.5 mg, 300 µg per lonidine hydrochlorideInj 150 µg per ml, 1 mlTab 25 µgTab 150 µgCatapresDixaritCatapres2012ClopidogrelTab 75 mgApo-Clopidogrel2013ClotrimazoleVaginal crm 1% with applicatorVaginal crm 2% with applicatorClomazolClomazol2013Coal tarSoln BPMidwest2013ColchicineTab 500 µgColgout2013CrotamitonCrm 10%Itch-Soothe2012Cyclizine hydrochlorideTab 50 mgNausicalm2012CyclophosphamideTab 50 mgCycloblastin2013Cyproterone acetateTab 50 mg & 100 mgSiterone2012DexamethasoneEye drops 0.1%Maxidex2013Dexamethasone sodiumphosphateInj 4 mg per ml, 1 ml & 2 mlHospira2013Dextrose with electrolytesSoln with electrolytesPedialyte – FruitPedialyte –BubblegumPedialyte – Plain2013Diclofenac sodiumTab EC 25 mg & 50 mgDiclofenac Sandoz2012Dihydrocodeine tartrateTab long-acting 60 mgDHC Continus2013Diltiazem hydrochlorideTab 30 mg & 60 mgCap long-acting 120 mg, 180 mg &240 mgDilzemCardizem CDDocusate sodium withsennosidesTab 50 mg with total sennosides 8mgLaxsol2013Donepezil hydrochlorideTab 5 mg & 10 mgDonepezil-Rex2012Doxazosin mesylateTab 2 mg & 4 mgApo-Doxazosin2014EnalaprilTab 5 mg, 10 mg & 20 mgArrow-Enalapril2012Enoxaparin sodium(low molecular weight heparin)Inj 20 mg, 40 mg, 60 mg, 80 mg, 100mg, 120 mg & 150 mgClexane2012EntacaponeTab 200 mgComtan2012Erythromycin ethyl succinateTab 400 mgE-Mycin201231/12/11*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated unless otherwise stated. Please note thatSole Subsidised Supply may have been awarded for a wider scope than just those presentation(s) listed in the above table.9
Sole Subsidised Supply Products – cumulative to August 2011Generic NamePresentationBrand Name Expiry Date*EscitalopramTab 10 mg & 20 mgLoxalate2013EthinyloestradiolTab 10 µgNZ Medical andScientific2012Etidronate disodiumTab 200 mgArrow-Etidronate2012ExemestaneTab 25 mgAromasin2014FelodipineTab long-acting 5 mgTab long-acting 10 mgFelo 5 ERFelo 10 ER2012FentanylTransdermal patch 12.5 µg perhour, 25 µg per hour, 50 µg perhour, 75 µg per hour, 100 µg perhourMylan FentanylPatch2013Ferrous sulphateOral liq 30 mg per 1 ml (6 mgelemental per 1 ml)Ferodan2013Flucloxacillin sodiumCap 250 mg & 500 mgGrans for oral liq 125 mg per 5 mlGrans for oral liq 250 mg per 5 mlAFTAFTAFT2012FluorometholoneEye drops 0.1%FML2012Fluoxetine hydrochlorideCap 20 mgTab dispersible 20 mg, scoredFluoxFluox2013FlutamideTab 250 mgFlutamin2013Fluticasone propionateMetered aqueous nasal spray,50 µg per doseFlixonase Hayfever &AllergyFurosemideInj 10 mg per ml, 2 mlTab 40 mgFrusemide-ClarisDiurin 4020132012Fusidic acidCrm 2%Oint 2%FobanFoban2013GabapentinCap 100 mg, 300 mg & 400 mgNupentinGemfibrozilTab 600 mgLipazil2013Gentamicin sulphateInj 40 mg per ml, 2 j 5 mg per ml, 1 mlOral liq 2 mg per mlTab 500 µg, 1.5 mg & 5 mgSerenaceSerenaceSerenace2013HydrocortisoneInj 50 mg per ml, 1 mlTab 5 mg & 20 mgSolu-CortefDouglas20132012Hydrocortisone acetateRectal foam 10%, CFC-free (14applications)Colifoam2012Hydrocortisone withmiconazoleCrm 1% with miconazole nitrate 2%Micreme H2013HydroxocobalaminInj 1 mg per ml, 1 mlABMHydroxocobalamin2012Hydroxychloroquine sulphateTab 200 mgPlaquenil20121031/1/1331/7/12*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated unless otherwise stated. Please note thatSole Subsidised Supply may have been awarded for a wider scope than just those presentation(s) listed in the above table.
Sole Subsidised Supply Products – cumulative to August 2011Generic NamePresentationBrand Name Expiry Date*IbuprofenOral liq 100 mg per 5 mlFenpaed2013IndapamideTab 2.5 mgDapa-Tabs2013Ipratropium bromideNebuliser soln, 250 µg per ml, 1 ml& 2 mlUnivent2013Isosorbide mononitrateTab 20 mgTab long-acting 40 mgIsmo 20Corangin2014IsotretinoinCap 10 mg & 20 mgOratane2012ItraconazoleCap 100 mgItrazole2013LactuloseOral liq 10 g per 15 mlLaevolac2013LamivudineOral liq 10 mg per mlTab 150 mg3TC3TC2013LatanoprostEye drops 50 µg per mlHysite2012LetrozoleTab 2.5 mgLetara2012LevonorgestrelSubdermal implant (2 x 75 mg rods)Jadelle31/12/13Lignocaine hydrochlorideInj 1%, 5 ml & 20 mlXylocaine2013Lignocaine with prilocaineCrm 2.5% with prilocaine 2.5%(5 g tubes)Crm 2.5% with prilocaine 2.5%;30 g OPEMLA2013LisinoprilTab 5 mg, 10 mg & 20 mgArrow-Lisinopril2012Loperamide hydrochlorideCap 2 mgDiamide Relief2013LoratadineOral liq 1 mg per mlTab 10 mgLorapaedLoraclear HayfeverRelief2013LorazepamTab 1 mg & 2.5 mgAtivan2013MalathionLiq 0.5%Shampoo 1%A-LicesA-Lices2013Mask for Spacer DeviceDeviceForemount Child’sSilicone MaskMegestrol acetateTab 160 mgApo-Megestrol2012MercaptopurineTab 50 mgPurinethol2013MesalazineEnema 1 g per 100 mlPentasa2012Metformin hydrochlorideTab immediate-release 500 mg &850 mgApotex2012Methadone hydrochlorideTab 5 mgOral liq 2 mg per mlOral liq 5 mg per mlOral liq 10 mg per mlMethatabsBiodoneBiodone ForteBiodone Extra Forte20132012MethotrexateInj 25 mg per ml, 2 ml & 20 mlTab 2.5 mg & 10 mgHospiraMethoblastin20132012EMLA30/9/11*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated unless otherwise stated. Please note thatSole Subsidised Supply may have been awarded for a wider scope than just those presentation(s) listed in the above table.11
Sole Subsidised Supply Products – cumulative to August 2011Generic NamePresentationBrand Name Expiry Date*MethylprednisoloneTab 4 mg & 100 mgMedrol2012Methylprednisolone sodiumsuccinateInj 40 mg per ml, 1 mlInj 62.5 mg per ml, 2 mlInj 500 mgInj 1 etoclopramide hydrochlorideTab 10 mgMetamide2014MoclobemideTab 150 mg & 300 mgApo-Moclobemide2012Mometasone furoateCrm 0.1%Oint 0.1%m-Mometasonem-Mometasone2012Morphine hydrochlorideOral liq 1 mg per mlOral liq 2 mg per mlOral liq 5 mg per mlOral liq 10 mg per mlRA-MorphRA-MorphRA-MorphRA-Morph2012Morphine sulphateCap long-acting 10 mg, 30 mg,60 mg & 100 mgTab immediate release 10 mg &20 mgm-Elson2013Sevredol2012Morphine tartrateInj 80 mg per ml, 1.5 ml & 5 mlHospira2013Mucilaginous laxativesDryKonsyl-D2013NaproxenTab 250 mgTab 500 mgNoflam 250Noflam 5002012NevirapineOral suspension 10 mg per ml2012Tab 200 mgViramuneSuspensionViramuneNicotineLozenge 1 mg & 2 mgPatch 7 mg, 14 mg & 21 mgHabitrolHabitrol2014NorethisteroneTab 350 µgNoriday 282012NystatinCap 500,000 uTab 500,000 uNilstatNilstat2013OndansetronTab disp 4 mg & 8 mgDr Reddy’sOndansetronDr Reddy’sOndansetron2013Tab 4 mg & 8 mgOxytocinInj 5 iu per ml, 1 mlInj 10 iu per ml, 1 mlInj 5 iu with ergometrine maleate 500µg per ml, 1 Tab 20 mg & 40 mgDr Reddy’sPantoprazole2013Paraffin liquid with soft whiteparaffinEye oint with soft white paraffinLacri-Lube2013Paroxetine hydrochlorideTab 20 mgLoxamine2013Peak Flow MeterLow range and Normal rangeBreath-Alert1230/9/11*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated unless otherwise stated. Please note thatSole Subsidised Supply may have been awarded for a wider scope than just those presentation(s) listed in the above table.
Sole Subsidised Supply Products – cumulative to August 2011Generic NamePresentationBrand Name Expiry Date*Pegylated interferon alpha-2AInj 135 µg prefilled syringeInj 180 µg prefilled syringeInj 135 µg prefilled syringe x 4 withribavirin tab 200 mg x 112Inj 135 µg prefilled syringe x 4 withribavirin tab 200 mg x 168Inj 180 µg prefilled syringe x 4 withribavirin tab 200 mg x 112Inj 180 µg prefilled syringe x 4 withribavirin tab 200 mg x 168PegasysPegasysPegasys RBVCombination PackPegasys RBVCombination PackPegasys RBVCombination PackPegasys RBVCombination PackPhenoxymethylpenicillin(Pencillin V)Cap potassium salt 250 mg &500 mgGrans for oral liq 125 mg per 5 mlGrans for oral liq 250 mg per 5 mlCilicaine VKPindololTab 5 mg, 10 mg & 15 mgApo-Pindolol2012PioglitazoneTab 15 mg, 30 mg & 45 mgPizaccord2012PizotifenTab 500 µgSandomigran2012Potassium chlorideTab long-acting 600 mgSpan-K2012Prednisone sodium phosphateOral liq 5 mg per mlRedipred2012Pregnancy tests – hCG urineCassetteInnovacon hCG OneStep Pregnancy Test2012Promethazine hydrochlorideOral liq 5 mg per 5 mlPromethazineWinthrop Elixir2012Quinine sulphateTab 300 mgQ 3002012RifabutinCap 150 mgMycobutin2013Ropinirole hydrochlorideTab 0.25 mg, 1 mg, 2 mg & 5 mgRopin2013RoxithromycinTab 150 mg & 300 mgArrowRoxithromycin2012SalbutamolOral liq 2 mg per 5 mlNebuliser soln, 1 mg per ml, 2.5 mlNebuliser soln, 2 mg per ml, 2.5 mlSalapinAsthalinAsthalin20132012Salbutamol with ipratropiumbromideNebuliser soln, 2.5 mg withipratopium bromide 0.5 mg per vial,2.5 mlDuolin2012Selegiline hydrochlorideTab 5 mgApo-Selegiline2012SertralineTab 50 mg & 100 mgArrow-Sertraline2013Sodium chlorideInj 23.4%, 20 mlBiomed2013Sodium citrate with sodiumlauryl sulphoacetateEnema 90 mg with sodium laurylsulphoacetate 9 mg per ml, 5 mlMicolette2013Sodium citro-tartrateGrans effervescent 4 g sachetsUral2013Sodium cromoglycateEye drops 2%Nasal spray, 4%RexacromRex2013201231/12/122013AFTAFT*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated unless otherwise stated. Please note thatSole Subsidised Supply may have been awarded for a wider scope than just those presentation(s) listed in the above table.13
Sole Subsidised Supply Products – cumulative to August 2011Generic NamePresentationBrand Name Expiry Date*SomatropinInj cartridge 16 iu (5.3 mg)Inj cartridge 36 iu (12 mg)GenotropinGenotropinSotalolTab 80 mg & 160 mgMylanSpacer Device230 ml, autoclavable & single patientSpace Chamber31/12/12201230/9/11SpironolactoneTab 25 mg & 100 mgSpirotone2013SumatriptanTab 50 mg & 100 mgArrow-Sumatriptan2013Tamsulosin hydrochlorideCap 400 µgTamsulosin-Rex2013Terazosin hydrochlorideTab 1 mg, 2 mg & 5 mgArrow2013Testosterone undecanoateCap 40 mgArrow-Testosterone2012Timolol maleateTab 10 mgApo-Timol2012Tranexamic acidTab 500 mgCycklokapron2013TropisetronCap 5 mgNavoban2012Vitamin B complexTab, strong, BPCB-PlexADE2013VitaminsTab (BPC cap strength)MultiADE2013Zidovudine [AZT]Cap 100 mgOral liq 10 mg per mlRetrovirRetrovir2013August changes in bold14*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated unless otherwise stated. Please note thatSole Subsidised Supply may have been awarded for a wider scope than just those presentation(s) listed in the above table.
Check your Schedule for full detailsSchedule page refSubsidy Brand or(Mnfr’s price) Generic Mnfr Per fully subsidisedNew ListingsEffective 1 August 201129OMEPRAZOLE Cap 10 mg . 2.91 Cap 20 mg . 3.78 Cap 40 mg . 5.57909090 Omezol Relief Omezol Relief Omezol Relief83FLUCONAZOLEPowder for oral suspension 10 mg per ml – SpecialAuthority see SA1148– Retail pharmacy. 34.5635 ml Diflucan SA1148 Special Authority for SubsidyInitial application from any relevant practitioner. Approvals valid for 6 weeks for applications meeting thefollowing criteria:Both:1. Patient requires prophlaxis for, or treatment of systemic candidiasis; and2. Patient is unable to swallow capsules.Renewal from any relevant practitioner. Approvals valid for 6 weeks for applications meeting the followingcriteria:Both:1. Patient requires prophlaxis for, or treatment of systemic candidiasis; and2. Patient is unable to swallow capsules.119VENLAFAXINE – Special Authority see SA1061 – Retail pharmacyTab 37.5 mg . 18.6428 Arrow-VenlafaxineXRTab 75 mg . 37.2728 Arrow-VenlafaxineXRTab 150 mg . 45.6828 Arrow-VenlafaxineXREffective 1 July 20112937OMEPRAZOLE Powder – Only in combination . 42.50Only in extemporaneously compounded omeprazole suspension.PYRIDOXINE HYDROCHLORIDEa) No more than 100 mg per doseb) Only on a prescription Tab 25 mg – No patient co-payment payable . 2.205g Midwest90 PyridoxADE42DABIGATRANDabigatran will not be funded Close Control in amounts less than 4 weeks of treatment.Cap 75 mg – No more than 2 cap per day . . 148.0060 OP PradaxaCap 110 mg. 148.0060 OP PradaxaCap 150 mg. 148.0060 OP Pradaxa62PERMETHRINCrm 5% . . 4.20 Three months supply may be dispensed at one timeif endorsed “certified exemption” by the prescriber.30 g OP Lyderm Three months or six months, asapplicable, dispensed all-at-once15
Check your Schedule for full detailsSchedule page refSubsidy Brand or(Mnfr’s price) Generic Mnfr Per fully subsidisedNew listings – effective 1 July 2011 (continued)82CLINDAMYCINInj phosphate 150 mg per ml, 4 ml – Retail pharmacy Specialist . 160.0010109RALOXIFENE HYDROCHLORIDE – Special Authority see SA1138 – Retail pharmacyTab 60 mg. 53.7628 Dalacin C Evista SA1138 Special Authority for SubsidyInitial application from any relevant practitioner. Approvals valid without further renewal unless notified forapplications meeting the following criteria:Any of the following:1 History of one significant osteoporotic fracture demonstrated radiologically and documented bone mineraldensity (BMD) 2.5 standard deviations below the mean normal value in young adults (i.e. T-Score -2.5)(see Notes); or2 History of one significant osteoporotic fracture demonstrated radiologically, and either the patient is elderly,or densitometry scanning cannot be performed because of major logistical, technical or pathophysiologicalreasons. It is unlikely that this provision would apply to many patients under 75 years of age; or3 History of two significant osteoporotic fractures demonstrated radiologically; or4 Documented T-Score -3.0 (see Notes); or5 A 10-year risk of hip fracture 3%, calculated using a published risk assessment algorithm (e.g. FRAX orGarvan) which incorporates BMD measurements (see Notes); or6 Patient has had a prior Special Authority approval for zoledronic acid (Underlying cause – Osteoporosis) oralendronate (Underlying cause - Osteoporosis).Notes:a) BMD (including BMD used to derive T-Score) must be measured using dual-energy x-ray absorptiometry(DXA). Quantitative ultrasound and quantitative computed tomography (QCT) are not acceptable.b) Evidence used by the UK National Institute for Health and Clinical Excellence (NICE) in developing its guidanceindicates that patients aged 75 years and over who have a history of significant osteoporotic fracturedemonstrated radiologically are very likely to have a T-Score -2.5 and, therefore, do not require BMDmeasurement for raloxifene funding.c) Osteoporotic fractures are the incident events for severe (established) osteoporosis, and can be defined usingthe WHO definitions of osteoporosis and fragility fracture. The WHO defines severe (established) osteoporosisas a T-score below -2.5 with one or more associated fragility fractures. Fragility fracturesare fractures that occur as a result of mechanical forces that would not ordinarily cause fracture (minimaltrauma). The WHO has quantified this as forces equivalent to a fall from a standing height or less.d) A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of avertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of theseheights compared to the vertebral body above or below the affected vertebral body.109TERIPARATIDE – Special Authority see SA11339 – Retail pharmacyInj 250 μg per ml, 2.4 ml . . 490.001 Forteo SA1139 Special Authority for SubsidyInitial application from any relevant practitioner. Approvals valid for 18 months for applications meeting thefollowing criteria:All of the following:1 The patient has severe, established osteoporosis; and2 The patient has a documented T-score less than or equal to -3.0 (see Notes); and3 The patient has had two or more fractures due to minimal trauma; and4 The patient has experienced at least one symptomatic new fracture after at least 12 months’ continuoustherapy with a funded antiresorptive agent at adequate doses (see Notes).Notes:continued.Patients pay a manufacturer’s surcharge whenthe Manufacturer’s Price is greater than the Subsidy16S29Unapproved medicine supplied under Section 29‡ safety cap reimbursedSole Subsidised Supply
Check your Schedule for full detailsSchedule page refSubsidy Brand or(Mnfr’s price) Generic Mnfr Per fully subsidisedNew listings – effective 1 July 2011 (continued)continued.a) The bone mineral density (BMD) measurement used to derive the T-score must be made using dual-energyx-ray absorptiometry (DXA). Quantitative ultrasound and quantitative computed tomography (QCT) are notacceptable.b) Antiresorptive agents and their adequate doses for the purposes of this Special Authority are definedas: alendronate sodium tab 70 mg or tab 70 mg with cholecalciferol 5,600 iu once weekly; raloxifenehydrochloride tab 60 mg once daily; zoledronic acid 5 mg per year. If an intolerance of a severitynecessitating permanent treatment withdrawal develops during the use of one antiresorptive agent, analternate antiresorptive agent must be trialled so that the patient achieves the minimum requirement of 12months’ continuous therapy.c) A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of avertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of theseheights compared to the vertebral body above or below the affected vertebral body.d) A maximum o
Curam Curam 2012 Ascorbic acid Tab 100 mg Vitala-C 2013 Aspirin Tab 100 mg Tab dispersible 300 mg Ethics Aspirin EC Ethics Aspirin 2013 Atenolol Tab 50 mg & 100 mg Atenolol Tablet USP 2012 Atropine sulphate Inj 600 µg, 1 ml AstraZeneca 2012 Azathioprine Tab 50 mg Inj 50 mg Imuprine Imuran 2013 Azithromycin Tab 500 mg Arrow-Azithromycin 2012
